Standard maintenance: - Type I-II: 0.5 mg twice per week - Type III-IV: 0.5 mg once per week - Type V-VI: 0.5 mg every 2-3 weeks Alternative approach: Some users prefer a single larger weekly dose (1.0 mg once per week instead of 0.5 mg twice per week)
Thymosin Alpha-1 An immune-modulating peptide approved as a pharmaceutical product in more than 30 countries for applications including hepatitis B, hepatitis C, and immune adjuvant therapy in oncology
Diagnosis of acute pancreatitis typically requires at least two of the following three criteria (Atlanta classification): characteristic abdominal pain, serum lipase or amylase elevated to at least three times the upper limit of normal, and imaging findings consistent with pancreatic inflammation
This action may lead to a more even skin tone and a brighter complexion
While our study is limited by a small sample size and retrospective data collection procedure, we nonetheless thoroughly investigated clinical and biochemical data and compared the clinical features of euDKA and hyDKA
Adverse events were also reported, including acute pancreatitis, severe hypoglycaemia and gastrointestinal side effects
